Furthermore, numerous investigations have found unusually high PROX1 expression in a variety of systemic malignant tumors, including neuroblastoma, colon cancer, kidney cancer, gastric cancer, esophageal squamous cell carcinoma, and hepatocellular carcinoma [7, 9]. This evidence concerns the gene PROX1 and neuroblastoma.